J Ethnopharmacol:年龄相关性黄斑变性不可忽视的中医治疗选择

2022-06-19 August MedSci原创

年龄相关性黄斑变性 (AMD) 是一种慢性神经退行性疾病,可导致老年人群中不可逆的中心视力丧失。传统中药 (TCM),包括方剂、针灸和草药,已用于治疗 AMD 已有数千年的历史。

年龄相关性黄斑变性(AMD)是一种以视网膜黄斑区神经感觉视网膜、视网膜色素上皮(RPE)和脉络膜毛细血管进行性变性为特征的眼部疾病。预测表明,2020年全球约有2亿人受到AMD的影响,预计到2040年将有约3亿人受到影响。AMD有两种类型,渗出型或“湿”型,伴有脉络膜新生血管,以及更常见的萎缩型或“干”型,伴有光感受器和视网膜色素上皮的地理萎缩。

目前没有理想的治疗方法可用于干性AMD;尽管抗VEGF(血管内皮生长因子)治疗通常有助于稳定湿性AMD患者的疾病进展和改善视觉功能。然而,一些患者对抗VEGF治疗反应不佳,玻璃体内注射的给药方式可能导致不良并发症,如视网膜脱离和眼内炎症。这激发了世界各地医学研究人员的兴趣,但由于缺乏高质量的随机对照试验和系统评价的研究成果,限制了中医药在这一领域的影响力。鉴于现代医学采用的各种方法迄今为止取得的成功有限,中医药代表了一种帮助识别有潜力改善EAMD治疗的药物的水平方法。

方法:使用中医药治疗AMD的相关术语和关键词,对PubMed数据库、Web of Science、谷歌学术和中国知识基础设施(CNKI)进行文献检索。还研究了相关书籍、博士和硕士论文。

结果:以中医为基础的 AMD 解释已为理解中医方剂和针灸对 AMD 的作用奠定了理论基础。还详细讨论了常见中草药的可能作用机制。

结论:中医药是治疗AMD患者的一种很有前景的选择。然而,缺乏严格的科学证据限制了中医疗法的影响和吸收。未来的研究应侧重于提高对中药疗法的作用机制和生物活性成分的理解。

综上所述,此文回顾了当前中医药治疗AMD的相关研究,并基于这些知识,为中医药在未来AMD治疗策略中的作用提供建议。希望能够突出中医药作为治疗AMD的一种价格合理的疾病调节剂的潜在重要性,并帮助更多的学者和临床医生研究AMD未来治疗的新方法。

 

原文:Li Y, Li X, Li X, Zeng Z, Strang N, Shu X, Tan Z. Non-neglectable therapeutic options for age-related macular degeneration: A promising perspective from traditional Chinese medicine. J Ethnopharmacol. 2022 Jan 10;282:114531. doi: 10.1016/j.jep.2021.114531. Epub 2021 Aug 31. PMID: 34474141.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-06-27 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-10-24 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-06-19 医鸣惊人

    认真学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1787807, encodeId=d7641e87807ee, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 27 22:30:07 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996488, encodeId=3dc519964882b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Oct 24 16:30:07 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788485, encodeId=87bc1e88485f0, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 03:30:07 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772759, encodeId=849b1e727593f, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Sun Oct 23 10:30:07 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933512, encodeId=9bb7193351264, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 07 15:30:07 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908717, encodeId=fe691908e1728, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jan 17 15:30:07 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838078, encodeId=e5ba18380e8c5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Mar 15 12:30:07 CST 2023, time=2023-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227394, encodeId=777b122e3946d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jun 19 18:22:43 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376760, encodeId=a61813e6760ea, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463816, encodeId=79b6146381693, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jun 18 08:30:07 CST 2022, time=2022-06-18, status=1, ipAttribution=)]
    2022-06-18 huangdf

相关资讯

STTT:中药天然化合物治疗缺血性脑卒中

中风与人类疾病中的第二大死亡原因和第三大残疾原因有关,而 IS 特别占所有中风病例的 80% 以上。由于人口的快速增长和老龄化,IS 发病率随着年龄的增长而急剧增加。

Front Pharmacol:益生菌联合中药治疗溃疡性结肠炎的疗效和安全性

益生菌联合中药(TCM)是治疗溃疡性结肠炎(UC)的一种前瞻性疗法,其疗效和安全性亟待评估。

J Dermatolog Treat:中药治疗寻常型银屑病的证据和潜在机制

寻常型银屑病(PV)不仅影响患者的皮肤健康,还会增加患冠心病和糖尿病的风险,给患者带来身心伤害。其病机复杂,中医药的多靶点作用尤为有利。

J Ethnopharmacol:中医药治疗慢传输型便秘的研究进展

慢传输型便秘是一种常见的胃肠道疾病,严重影响患者的生活质量。目前,常规化学药物虽然在短期内能有效控制STC症状,但远期效果较差,副作用显着。在这方面,中医药 为 STC 治疗提供了机会。

J Integr Med:中草药治疗老年便秘,似乎效果更佳

便秘是一种常见的慢性肠道疾病,在老年人口中的发病率超过50%。补充和替代药物是一种成本效益高且令人满意的治疗便秘的方法,被老年人广泛使用。

Phytomedicine:中医视角下帕金森病的发病机制及治疗机制

帕金森病 (PD) 是第二常见的神经退行性疾病,目前尚无治疗方法可以改变其进展。中医药(TCM)以其独特的理论基础和临床疗效而备受关注。许多研究报道了中草药治疗 PD 的临床作用和药理机制。